| Literature DB >> 25881303 |
Xiang Zheng1, Jing Zhou2, Baozhen Zhang3, Jun Zhang4, James Wilson5, Liankun Gu6, Budong Zhu7, Jin Gu8, Jiafu Ji9, Dajun Deng10.
Abstract
BACKGROUND: CBX7 is a Polycomb group protein that shows variable expression changes in various cancers that are often contradictive. A mouse knockout experiment has validated the tumor suppressor role in carcinogenesis. The purpose of this study is to verify the tumor suppressor role of Cbx7 in human colon carcinomas (CC).Entities:
Mesh:
Substances:
Year: 2015 PMID: 25881303 PMCID: PMC4365772 DOI: 10.1186/s12885-015-1172-6
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Association of mRNA level and clinicopathological features of colon cancer patients
| Clinicopathological features |
| |||
|---|---|---|---|---|
| Colon cancer | Surgical margin | |||
| Age (years) | ≤62 | 42 |
| 2.42 (1.31-4.88) |
| >62 | 55 |
| 1.72 (0.98-4.43) | |
| Sex | Male | 49 | 2.04 (0.74-4.54) | 1.77 (0.97-4.00) |
| Female | 48 | 1.60 (0.90-3.40) | 2.22 (1.31-5.29) | |
| Location | Ascending/Transverse | 42 | 1.94 (1.05-4.52) | 1.70 (1.27-3.27) |
| Descending/Sigmoid | 37 | 1.90 (0.72-4.61) | 1.94 (1.04-6.26) | |
| Undefined | 18 | 1.29 (0.61-2.75) | 2.42 (1.20-7.74) | |
| Differentiation | Poor | 24 | 1.60 (0.89-3.59) | 1.60 (1.31-3.54) |
| Moderate/Well | 70 | 2.02 (0.76-4.59) | 2.22 (0.949-6.05) | |
| Vascular invasion | Absent | 69 | 1.95 (0.79-4.48) | 1.94 (1.27-5.25) |
| Present | 26 | 1.74 (0.69-4.13) | 1.90 (1.13-4.71) | |
| pTNM | I&II | 39 | 2.06 (1.01-4.54) | 1.94 (0.66-5.41) |
| III&IV | 58 | 1.63 (0.69-3.92) | 1.90 (1.30-4.66) | |
| Invasion | T1 ~ 2 | 5 | 5.77 (4.48-8.25) | 1.31 (0.30-3.09) |
| T3 | 51 | 1.40 (0.38-3.73) | 2.39 (0.94-5.83) | |
| T4 | 41 | 1.83 (0.96-3.81) | 1.82 (1.31-3.39) | |
| Lymph metastasis | Negative | 50 |
| 1.77 (1.18-4.63) |
| Positive | 47 |
| 2.22 (1.12-4.85) | |
| Distant metastasis | Negative | 69 | 2.04 (0.96-4.27) | 1.94 (1.08-4.95) |
| Positive | 29 | 1.31 (0.42-4.56) | 1.97 (1.22-5.15) | |
| Post-operative therapy | No | 48 | 1.93 (0.75-3.77) | 1.75 (1.03-5.03) |
| Yes | 49 | 1.64 (0.94-4.48) | 2.22 (1.27-4.00) | |
aAlu-normalized relative copy number (×10−4), the value is presented median (25% ~ 75% percentile); bMann–Whitney test, P = 0.007
Figure 1Correlation analysis between CBX7 expression in immunohistochemical (IHC) analysis and quantitative RT-PCR using different reference genes. (A) CBX7-IHC images for CC and SM samples from three patients; Strong nuclear CBX7 protein staining was mainly located in cancer cells (red-arrows) in the representative colon cancer (CC) tissues, but located in both glandular epithelial cells and lymphoid cells (blue-arrows) in the corresponding surgical margin (SM). (B) CBX7-IHC staining scores and GAPDH-normalized Cbx7 mRNA levels; (C) CBX7-IHC staining scores and Alu-normalized Cbx7 mRNA levels. The relative copy number of Cbx7 mRNA was determined from the difference in cycle threshold values between the target and reference genes.
Figure 2Correlation analysis between CBX7 expression in Western blot analysis and quantitative RT-PCR using different reference genes. (A) Detection of CBX7 protein in CC and SM samples using Western blot analysis; (B) Relative intensities of CBX7 protein to β-Actin and GAPDH-normalized Cbx7 mRNA levels; (C) Relative intensities of CBX7 protein to β-Actin and Alu-normalized Cbx7 mRNA levels.
Figure 3Comparison ofmRNA levels among Normal, CC and SM samples. The mRNA level represented as the ∆CT value between Alu and Cbx7 transcripts. A higher ∆CT value indicates a lower mRNA level.
Figure 4mRNA level in CCs correlates with prognosis. (A) ROC curve of CC metastasis used to classify patients as Cbx7-high or low (cut-off value = 7.45 × 10−5); the area under the curve (AUC) is 62.9% (P < 0.029); (B) Kaplan-Meier overall survival curves for patients classified as Cbx7 expression-low and –high (P = 0.001, log-rank test).
Multivariate analysis of overall survival in colon cancer patients
| Variable | Hazard ratio (95% CI) | |
|---|---|---|
| 3.16 (1.58-6.30) | 0.001 | |
| Vascular invasion | 3.43 (1.64-7.17) | 0.001 |
| pTNM | 4.13 (1.71-9.98) | 0.002 |
| Age | 1.31 (0.65-2.64) | 0.449 |
| Sex | 0.70 (0.38-1.29) | 0.255 |
| Differentiation | 0.79 (0.39-1.61) | 0.512 |
| Adjuvant therapy | 1.05 (0.55-2.01) | 0.888 |
Figure 5Enforcedoverexpression promotes migration of colon cancer cell lines. (A and B) Results of Transwell migration and Matrigel invasion tests using HCT116 cells transiently transfected with the Cbx7 expression vector for 48 hrs, respectively; (C and D) Results of Transwell migration and Matrigel invasion tests using SW480 cells transiently transfected with the Cbx7 expression vector for 48 hrs, respectively. The transfection efficiency is presented in Figure S2.
Figure 6Images of experimental pulmonary metastasis nodules of colon cancer SW480 cells with or withoutoverexpression in SCID mice. Slides are prepared along the maximum lung area for each mouse.